BidaskClub lowered shares of ANI Pharmaceuticals (NASDAQ:ANIP) from a buy rating to a hold rating in a report issued on Tuesday, BidAskClub reports.

Other analysts have also issued research reports about the stock. Zacks Investment Research lowered shares of ANI Pharmaceuticals from a buy rating to a hold rating in a research note on Friday, May 17th. Raymond James lowered shares of ANI Pharmaceuticals from a strong-buy rating to an outperform rating and upped their target price for the stock from $73.00 to $82.00 in a research note on Friday, May 10th. ValuEngine upgraded shares of ANI Pharmaceuticals from a hold rating to a buy rating in a research note on Thursday, May 9th. Canaccord Genuity reiterated a buy rating and issued a $90.00 target price (up previously from $80.00) on shares of ANI Pharmaceuticals in a research note on Monday, May 13th. Finally, Cantor Fitzgerald reiterated a buy rating and issued a $89.00 target price on shares of ANI Pharmaceuticals in a research note on Thursday, May 9th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. ANI Pharmaceuticals has an average rating of Buy and a consensus target price of $84.50.

ANIP stock opened at $69.68 on Tuesday. The stock has a market capitalization of $851.78 million, a price-to-earnings ratio of 15.11 and a beta of 2.23. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.67 and a current ratio of 0.92. ANI Pharmaceuticals has a 12 month low of $36.92 and a 12 month high of $74.00.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Thursday, May 9th. The specialty pharmaceutical company reported $1.30 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.05 by $0.25. The firm had revenue of $52.90 million for the quarter, compared to the consensus estimate of $50.57 million. ANI Pharmaceuticals had a net margin of 6.58% and a return on equity of 28.63%. The company’s revenue for the quarter was up 13.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.32 EPS. Equities research analysts forecast that ANI Pharmaceuticals will post 5.57 earnings per share for the current fiscal year.

In other news, Director David Nash bought 1,445 shares of ANI Pharmaceuticals stock in a transaction dated Friday, May 24th. The stock was purchased at an average price of $68.76 per share, for a total transaction of $99,358.20. Following the purchase, the director now directly owns 5,236 shares in the company, valued at approximately $360,027.36. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Arthur Przybyl sold 27,625 shares of the company’s stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $63.53, for a total transaction of $1,755,016.25. The disclosure for this sale can be found here. In the last quarter, insiders sold 78,536 shares of company stock valued at $5,340,131. Company insiders own 24.70% of the company’s stock.

Several large investors have recently modified their holdings of the stock. Financial Gravity Wealth Inc. bought a new stake in ANI Pharmaceuticals in the first quarter valued at approximately $54,000. Quantamental Technologies LLC increased its stake in ANI Pharmaceuticals by 169.4% in the first quarter. Quantamental Technologies LLC now owns 862 shares of the specialty pharmaceutical company’s stock valued at $61,000 after purchasing an additional 542 shares in the last quarter. South Dakota Investment Council bought a new stake in ANI Pharmaceuticals in the fourth quarter valued at approximately $45,000. BNP Paribas Arbitrage SA increased its stake in ANI Pharmaceuticals by 55,466.7% in the first quarter. BNP Paribas Arbitrage SA now owns 1,667 shares of the specialty pharmaceutical company’s stock valued at $118,000 after purchasing an additional 1,664 shares in the last quarter. Finally, Truvestments Capital LLC bought a new stake in ANI Pharmaceuticals in the first quarter valued at approximately $140,000. 63.92% of the stock is currently owned by institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.

Further Reading: What is a Leveraged Buyout (LBO)?

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.